TTY Biopharm Company Overview

  • Founded
  • 1960
Founded
  • Status
  • Public
  • Employees
  • 374
Employees
  • Stock Symbol
  • 4105
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $2.43
  • (As of Wednesday Closing)

TTY Biopharm Company General Information

Description

TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segment includes Oncology, Health Care, Anti-Infection, Domestic Cardiovascular and Gastrointestinal Drugs, and other segments. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

Contact Information

Website
www.tty.com.tw
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
ROCO
Primary Office
  • 3F., No.3-1, Park Street
  • Taipei, Nangang 115-03
  • Taiwan
+886 02 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TTY Biopharm Company Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.43 $2.44 $2.19 - $3.49 $606M 249M 521K $0.11

TTY Biopharm Company Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 633,440 626,336 679,113 607,138
Revenue 151,898 143,426 144,536 133,791
EBITDA 41,564 46,303 43,020 60,691
Net Income 26,715 31,397 29,128 48,441
Total Assets 349,633 335,597 318,955 296,019
Total Debt 54,688 76,470 52,716 49,170
Public Fundamental Data provided by Morningstar, Inc. disclaimer

TTY Biopharm Company Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore TTY Biopharm Company‘s full profile, request access.

Request a free trial

TTY Biopharm Company Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's o
Biotechnology
Taipei, Taiwan
374 As of 2008
00000000

000000

am, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute iru
0000000000000
Bangalore, India
00000 As of 0000
000.00
0000 0000-00-00
00000000 000.00

0000 000

mod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
000000000000000
Petach Tikva, Israel
00000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TTY Biopharm Company Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocon Formerly PE-Backed Bangalore, India 00000 000.00 00000000 000.00
0000 0000000000000 Corporate Backed or Acquired Petach Tikva, Israel 00000 00000 00000000000 00000
00000 Corporation Mumbai, India 00000 00000000
00000000 Corporation Basel, Switzerland 000000 000000000000
To view TTY Biopharm Company’s complete competitors history, request access »

TTY Biopharm Company Patents

TTY Biopharm Company Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2515930-A1 Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells Withdrawn 21-Dec-2009 0000000000
EP-2515930-A4 Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells Withdrawn 21-Dec-2009 0000000000 0
JP-2012502934-A Composition for inhibiting pathological angiogenesis Withdrawn 22-Sep-2008 00000000000
US-20120071405-A1 Composition of inhibiting pathological angiogenesis Abandoned 22-Sep-2008 00000000000 0
EP-2347761-A1 A composition with inhibition activity on pathological angiogenesis Withdrawn 22-Sep-2008 A61K38/1808
To view TTY Biopharm Company’s complete patent history, request access »

TTY Biopharm Company Executive Team (1)

Name Title Board Seat Contact Info
Jeff Shih Executive
To view TTY Biopharm Company’s complete executive team members history, request access »

TTY Biopharm Company Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TTY Biopharm Company Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 01-Aug-2017 00000 0000 Drug Discovery
0000000 00000 01-Dec-2012 0000000000 Pharmaceuticals
PharmaEngine 01-Jan-2004 Early Stage VC Biotechnology
To view TTY Biopharm Company’s complete investments and acquisitions history, request access »

TTY Biopharm Company Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000000 01-Jan-2004 00000 00000 00 Completed
  • 2 buyers
To view TTY Biopharm Company’s complete exits history, request access »